Tenaya Therapeutics (TNYA) News Today → HUGE BUY ALERT: Move Fast, Musk... (From Stansberry Research) (Ad) Free TNYA Stock Alerts $4.40 +0.12 (+2.80%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 4:05 PM | globenewswire.comTenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from AnalystsMay 2, 2024 | globenewswire.comTenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 14, 2024 | finance.yahoo.comInstitutions own 33% of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares but private equity firms control 44% of the companyApril 13, 2024 | marketbeat.comShort Interest in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Increases By 21.2%Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 3,090,000 shares, a growth of 21.2% from the March 15th total of 2,550,000 shares. Based on an average trading volume of 609,900 shares, the days-to-cover ratio is currently 5.1 days. Currently, 5.0% of the company's shares are sold short.April 5, 2024 | markets.businessinsider.comTenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy RatingMarch 29, 2024 | markets.businessinsider.comOptimistic Buy Rating for Tenaya Therapeutics Based on Promising Gene Therapy Pipeline and Upcoming Clinical MilestonesMarch 26, 2024 | finance.yahoo.com20 Countries with the Highest Heart Disease Deaths Per CapitaMarch 21, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)March 21, 2024 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Stock Rating Reaffirmed by Chardan CapitalChardan Capital reissued a "buy" rating and set a $20.00 target price on shares of Tenaya Therapeutics in a report on Thursday.March 21, 2024 | marketbeat.comLeerink Partnrs Brokers Increase Earnings Estimates for Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Investment analysts at Leerink Partnrs boosted their Q1 2024 earnings per share (EPS) estimates for Tenaya Therapeutics in a report released on Tuesday, March 19th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will poMarch 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Sera Prognostics (SERA), Tenaya Therapeutics (TNYA)March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Sera Prognostics (SERA)March 20, 2024 | finance.yahoo.comTenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial ResultsMarch 20, 2024 | marketbeat.comTenaya Therapeutics (NASDAQ:TNYA) Given New $18.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group reduced their price objective on shares of Tenaya Therapeutics from $19.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday.March 19, 2024 | markets.businessinsider.comBuy Rating Justified by Tenaya Therapeutics’ Strong Financials and Promising Cardiovascular Pipeline ProgressMarch 19, 2024 | finanznachrichten.deTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from AnalystsShares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year prMarch 19, 2024 | marketbeat.comTenaya Therapeutics' (TNYA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Tuesday.March 18, 2024 | investorplace.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023March 18, 2024 | globenewswire.comTenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comTenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications MedicineMarch 16, 2024 | insidertrades.comTimothy Hoey Sells 3,300 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) StockMarch 11, 2024 | marketbeat.comGSA Capital Partners LLP Buys 240,082 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)GSA Capital Partners LLP grew its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 194.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 363,493 shares of the company's stock aftMarch 8, 2024 | marketbeat.comFmr LLC Sells 567,488 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Fmr LLC lowered its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 15.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,186,751 shares of the company's stock after selling 567,488 shares during theFebruary 27, 2024 | globenewswire.comTenaya Therapeutics to Participate in Upcoming March Investor ConferencesFebruary 26, 2024 | globenewswire.comTenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature CommunicationsFebruary 24, 2024 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Acquired by Barclays PLCBarclays PLC increased its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 2,635.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 249,558 shares of the company's stock after purchasing an additional 240,436 shares during the period. BarclaFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 16, 2024 | finance.yahoo.comTNYA Mar 2024 7.500 putFebruary 16, 2024 | finance.yahoo.comTNYA Apr 2024 7.500 putFebruary 13, 2024 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given a consensus recommendation of "Buy" by the seven analysts that are currently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month priFebruary 9, 2024 | msn.comTenaya Therapeutics Announces Speculative Offering OutlookFebruary 9, 2024 | finance.yahoo.comWall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a BetFebruary 9, 2024 | msn.comTenaya Therapeutics Secures $50 Million in Share SaleFebruary 8, 2024 | markets.businessinsider.comTenaya Announces Pricing Of $50 Mln Underwritten Offering; Stock UpFebruary 8, 2024 | finance.yahoo.comTenaya Therapeutics Announces Pricing of Underwritten OfferingFebruary 6, 2024 | msn.com5 Russell 2000 Stocks Poised to Give the Large Caps a Run for Their MoneyJanuary 26, 2024 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's WhyJanuary 26, 2024 | seekingalpha.comDBX, CMPS and EWBC are among after hour moversJanuary 22, 2024 | marketbeat.comAnalysts Offer Predictions for Tenaya Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:TNYA)Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2023 earnings per share estimates for shares of Tenaya Therapeutics in a note issued to investors on Wednesday, January 17th. Leerink Partnrs analyst M. Foroohar now forecasts that the cJanuary 14, 2024 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest UpdateTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,370,000 shares, an increase of 19.7% from the December 15th total of 1,980,000 shares. Based on an average daily trading volume, of 348,100 shares, the short-interest ratio is presently 6.8 days. Approximately 5.3% of the shares of the stock are short sold.January 3, 2024 | finance.yahoo.comTenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 30, 2023 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Down 23.6% in DecemberTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 1,980,000 shares, a decline of 23.6% from the November 30th total of 2,590,000 shares. Based on an average daily volume of 369,900 shares, the short-interest ratio is presently 5.4 days. Currently, 4.4% of the company's shares are short sold.December 25, 2023 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has received a consensus rating of "Buy" from the seven analysts that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analDecember 1, 2023 | msn.comLeerink Partners Initiates Coverage of Tenaya Therapeutics (TNYA) with Outperform RecommendationNovember 24, 2023 | morningstar.comTenaya Therapeutics Inc TNYANovember 21, 2023 | finance.yahoo.comTenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare ConferenceNovember 10, 2023 | markets.businessinsider.comStrong Financial Performance and Cardiovascular Therapy Developments Support Buy Rating for Tenaya TherapeuticsNovember 9, 2023 | msn.comTenaya Therapeutics GAAP EPS of -$0.39 beats by $0.09 Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Revolutionizing the Green Energy Space and Building Shareholder Value Along the Way (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely! Learn how this American company is leading the lithium-ion revolution TNYA Media Mentions By Week TNYA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNYA News Sentiment▼1.450.57▲Average Medical News Sentiment TNYA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNYA Articles This Week▼21▲TNYA Articles Average Week Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aura Biosciences News Today MeiraGTx News Today Black Diamond Therapeutics News Today Precigen News Today Jasper Therapeutics News Today Caribou Biosciences News Today Solid Biosciences News Today SOPHiA GENETICS News Today Ocugen News Today Tourmaline Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNYA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpax Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
